Pages

Tuesday, March 28, 2017

It's bleak to me

To this non-expert, non-lawyer, the never-ending saga of who is to be credited with the patent rights to CRISPR gene-editing technology seems reminiscent of Charles Dickens' Bleak House tale of interminable litigation:

The European Patent Office (EPO) yesterday (March 23) announced its intention to award a broad-strokes patent for CRISPR gene-editing technology to the University of California, Berkeley, the University of Vienna, and Emmanuelle Charpentier (formerly of the Helmholtz Centre for Infection Research). The claims include the use of CRISPR across prokaryotic and eukaryotic cells and organisms, hitting upon the point of contention in a recent patent interference decision in the United States. In that case, the US Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) denied UC Berkeley the rights over the use of the technology in eukaryotes—the money-making application for CRISPR—leaving that intellectual property with the Broad Institute of MIT and Harvard.
“We are excited that this patent will issue based on the foundational research we published with Emmanuelle Charpentier and the rest of our team,” Jennifer Doudna, the leader of the UC Berkeley contingent of the international team, said in a statement. “We look forward to the continued applications of gene-editing technology to solve problems in human health and agriculture.”
According to EPO procedures, the international team’s patent is all but granted (a few logistical details, such as finalizing the text and paying fees, remain to be settled). “Substantively, the decision is made,”said Catherine Coombes, a senior patent attorney with HGF Limited in the U.K. who last year wrote an opinion for The Scientist on the CRISPR patent situation in Europe. “The EPO, by granting this [patent], is not being swayed by the PTAB decision in the U.S. . . . The claims are very broad.”
The Broad Institute will now have nine months to file its opposition to the EPO patent’s claims. Coombes said she expects that will happen. “We can, of course, expect multiple oppositions upon grant,” Coombes said. “No doubt, these will concentrate heavily on why UC Berkeley shouldn’t be entitled to their earliest [filing] date” for all the claims listed.
Unlike the parallel process in the U.S., the UC Berkeley–Vienna–Helmholtz Centre team will have multiple opportunities to amend its claims, noted Kevin Noonan, a biotech expert and partner at the Chicago-based IP law firm McDonnell Boehnen Hulbert & Berghoff. The team “could ultimately get more narrow claims,” he said. If that’s the case, he added, the situation in Europe could end up the way the US IP landscape is expected to play out, with UC Berkeley owning rights to CRISPR’s use in prokaryotes, and the Broad Institute owning CRISPR rights in eukaryotes. Otherwise, the UC Berkeley team could end up with intellectual property rights over CRISPR technology in both prokaryotic and eukaryotic cells.
The EPO’s decisions should not have any impact on future proceedings at the USPTO, said Noonan. “The US courts and patents laws don’t care what the Europeans do,” he said...

No comments: